Aragon Pharmaceuticals (San Diego, CA) a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer, closed a $8M Series A financing. Participants include The Column Group and OrbiMed Advisors.